Search

Your search keyword '"Zuze, Takondwa"' showing total 27 results
Start Over Author "Zuze, Takondwa"
27 results on '"Zuze, Takondwa"'

1. Outcomes and prognostic factors for women with breast cancer in Malawi

Author

Youngblood, Victoria M., Nyirenda, Ruth, Nyasosela, Richard, Zuze, Takondwa, Yang, Yi, Kudowa, Evaristar, Moses, Agnes, Kincaid, Jennifer, Kajombo, Chifundo, Kampani, Coxcilly, Chimzimu, Fred, Mulenga, Maurice, Chilima, Chrissie, Ellis, Grace K., Seguin, Ryan, Chagomerana, Maganizo, Maine, Rebecca, Jordan, Sheryl, Charles, Anthony, Lee, Clara, Gopal, Satish, and Tomoka, Tamiwe

Published
2020

3. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial

Author

Kimani, Stephen, Painschab, Matthew S, Kaimila, Bongani, Kasonkanji, Edwards, Zuze, Takondwa, Tomoka, Tamiwe, Mulenga, Maurice, Nyasosela, Richard, Chikasema, Maria, Mtangwanika, Asekanadziwa, Chawinga, Mena, Mhango, Wilberforce, Nicholas, Simon, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Lilly, Amy, Randall, Cara, Seguin, Ryan, Westmoreland, Katherine D, Montgomery, Nathan D, Fedoriw, Yuri, and Gopal, Satish

Published
2021
Full Text
View/download PDF

5. Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations

Author

Iwai, Yoshiko, primary, Toumbou, Kadiata, additional, Zuze, Takondwa, additional, Morgan, Jenny S., additional, Simwinga, Lusayo, additional, Wright, Sarah T., additional, Fedoriw, Yuri, additional, Oladeru, Oluwadamilola T., additional, Balogun, Onyinye D., additional, Roberson, Mya L., additional, Olopade, Olufunmilayo I., additional, Tomoka, Tamiwe, additional, and Elmore, Shekinah N.C., additional

Published
2023
Full Text
View/download PDF

7. Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy

Author

Gondwe, Yolanda, primary, Kudowa, Evaristar, additional, Tomoka, Tamiwe, additional, Kasonkanji, Edwards D., additional, Kaimila, Bongani, additional, Zuze, Takondwa, additional, Mumba, Noel, additional, Kimani, Stephen, additional, Mulenga, Maurice, additional, Chimzimu, Fred, additional, Kampani, Coxcilly, additional, Randall, Cara, additional, Lilly, Amy, additional, Gopal, Satish, additional, Fedoriw, Yuri, additional, and Painschab, Matthew, additional

Published
2022
Full Text
View/download PDF

8. ‘Discovering’ primary effusion lymphoma in Malawi

Author

Dhungel, Bal Mukunda, Montgomery, Nathan D., Painschab, Matthew S., Mulenga, Maurice, Tomoka, Tamiwe, Kaimila, Bongani, Zuze, Takondwa, Kasonkanji, Edwards, Kampani, Coxcilly, Chimzimu, Fred, Randall, Cara, Krysiak, Robert, Seguin, Ryan, Fedoriw, Yuri, and Gopal, Satish

Published
2018
Full Text
View/download PDF

9. Plasmablastic lymphoma in Malawi

Author

Zuze, Takondwa, Painschab, Matthew S., Seguin, Ryan, Kudowa, Evarista, Kaimila, Bongani, Kasonkanji, Edwards, Tomoka, Tamiwe, Dhungel, Bal Mukunda, Mulenga, Maurice, Chikasema, Maria, Tewete, Blessings, Ntangwanika, Asekanadziwa, Chiyoyola, Sarah, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Montgomery, Nathan D., Fedoriw, Yuri, and Gopal, Satish

Published
2018
Full Text
View/download PDF

10. Clinical Characteristics of Incident Lymphoma in Malawi before and after Implementation of Universal Anti-Retroviral Therapy

Author

Gondwe, Yolanda, primary, Kudowa, Evaristar, additional, Tomoka, Tamiwe, additional, Randall, Cara, additional, Lilly, Amy, additional, Kasonkanji, Edwards, additional, Kaimila, Bongani, additional, Zuze, Takondwa, additional, Mumba, Noel, additional, Kimani, Stephen, additional, Mulenga, Maurice, additional, Gopal, Satish, additional, Fedoriw, Yuri, additional, and Painschab, Matthew, additional

Published
2021
Full Text
View/download PDF

11. Abstract 88: Clinical Characteristics of Incident Lymphoma in Malawi before and after Implementation of Universal ART

Author

Gondwe, Yolanda, primary, Kudowa, Evaristar, additional, Painschab, Matthew, additional, Tomoka, Tamiwe, additional, Fedoriw, Yuri, additional, Kasonkanji, Edwards, additional, Kaimila, Bongani, additional, Zuze, Takondwa, additional, Mithi, Victor, additional, Mumba, Noel, additional, Kimani, Stephen, additional, and Mulenga, Maurice, additional

Published
2021
Full Text
View/download PDF

13. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi

Author

Kasonkanji, Edwards, Kamapani, Coxcilly, Kaimila, Bongani, Miller, Melissa B., Zuze, Takondwa, Gopal, Satish, Mulenga, Maurice, Damania, Blossom, Fedoriw, Yuri, Dittmer, Dirk P., Elliott, Avian, Randall, Cara, Painschab, Matthew, Sanders, Marcia K., Seguin, Ryan, Montgomery, Nathan D., Krysiak, Robert, Chimzimu, Fred, and Tomoka, Tamiwe

Subjects
hemic and lymphatic diseases
Abstract

Plasma Epstein-Barr virus (EBV) DNA measurement has established prognostic utility in EBV-driven lymphomas, where it serves as a circulating tumor DNA marker. The value of plasma EBV measurement may be amplified in sub-Saharan Africa (SSA), where advanced imaging and molecular technologies for risk stratification are not typically available. However, its utility in diffuse large B-cell lymphoma (DLBCL) is less certain, given that only a subset of DLBCLs are EBV-positive. To explore this possibility, we measured plasma EBV DNA at diagnosis in a cohort of patients with DLBCL in Malawi. High plasma EBV DNA at diagnosis (≥3.0 log10 copies/mL) was associated with decreased overall survival (OS) (P =.048). When stratified by HIV status, the prognostic utility of baseline plasma EBV DNA level was restricted to HIV-positive patients. Unexpectedly, most HIV-positive patients with high plasma EBV DNA at diagnosis had EBV-negative lymphomas, as confirmed by multiple methods. Even in these HIV-positive patients with EBV-negative DLBCL, high plasma EBV DNA remained associated with shorter OS (P =.014). These results suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV-positive patients with convincingly EBV-negative DLBCL, extending the potential utility of EBV measurement as a valuable and implementable prognostic marker in SSA.

Published
2020
Full Text
View/download PDF

15. High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

Author

Montgomery, Nathan D., primary, Randall, Cara, additional, Painschab, Matthew, additional, Seguin, Ryan, additional, Kaimila, Bongani, additional, Kasonkanji, Edwards, additional, Zuze, Takondwa, additional, Krysiak, Robert, additional, Sanders, Marcia K., additional, Elliott, Avian, additional, Miller, Melissa B., additional, Kampani, Coxcilly, additional, Chimzimu, Fred, additional, Mulenga, Maurice, additional, Damania, Blossom, additional, Tomoka, Tamiwe, additional, Fedoriw, Yuri, additional, Dittmer, Dirk P., additional, and Gopal, Satish, additional

Published
2019
Full Text
View/download PDF

16. Modified EPOCH for high‐risk non‐Hodgkin lymphoma in sub‐Saharan Africa

Author

Zuze, Takondwa, primary, Ellis, Grace K., additional, Kasonkanji, Edwards, additional, Kaimila, Bongani, additional, Nyasosela, Richard, additional, Nyirenda, Ruth, additional, Tomoka, Tamiwe, additional, Mulenga, Maurice, additional, Chikasema, Maria, additional, Tewete, Blessings, additional, Mtangwanika, Asekanadziwa, additional, Chiyoyola, Sarah, additional, Chimzimu, Fred, additional, Kampani, Coxcilly, additional, Mhango, Wilberforce, additional, Nicholas, Simon, additional, Randall, Cara, additional, Montgomery, Nathan D., additional, Fedoriw, George, additional, Westmoreland, Katherine D., additional, Painschab, Matthew S., additional, and Gopal, Satish, additional

Published
2019
Full Text
View/download PDF

17. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi

Author

Painschab, Matthew S., primary, Westmoreland, Kate D., additional, Kasonkanji, Edwards, additional, Zuze, Takondwa, additional, Kaimila, Bongani, additional, Waswa, Peter, additional, El-Mallawany, Nader Kim, additional, Tomoka, Tamiwe, additional, Mulenga, Maurice, additional, Montgomery, Nathan D., additional, Fedoriw, Yuri, additional, and Gopal, Satish, additional

Published
2019
Full Text
View/download PDF

18. High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi.

Author

Montgomery, Nathan D., Randall, Cara, Painschab, Matthew, Seguin, Ryan, Kaimila, Bongani, Kasonkanji, Edwards, Zuze, Takondwa, Krysiak, Robert, Sanders, Marcia K., Elliott, Avian, Miller, Melissa B., Kampani, Coxcilly, Chimzimu, Fred, Mulenga, Maurice, Damania, Blossom, Tomoka, Tamiwe, Fedoriw, Yuri, Dittmer, Dirk P., and Gopal, Satish

Subjects
DIFFUSE large B-cell lymphomas, CIRCULATING tumor DNA, EPSTEIN-Barr virus, HIV status, DNA, NANOTECHNOLOGY, LYMPHOMAS, GENETIC markers
Abstract

Plasma Epstein‐Barr virus (EBV) DNA measurement has established prognostic utility in EBV‐driven lymphomas, where it serves as a circulating tumor DNA marker. The value of plasma EBV measurement may be amplified in sub‐Saharan Africa (SSA), where advanced imaging and molecular technologies for risk stratification are not typically available. However, its utility in diffuse large B‐cell lymphoma (DLBCL) is less certain, given that only a subset of DLBCLs are EBV‐positive. To explore this possibility, we measured plasma EBV DNA at diagnosis in a cohort of patients with DLBCL in Malawi. High plasma EBV DNA at diagnosis (≥3.0 log10 copies/mL) was associated with decreased overall survival (OS) (P =.048). When stratified by HIV status, the prognostic utility of baseline plasma EBV DNA level was restricted to HIV‐positive patients. Unexpectedly, most HIV‐positive patients with high plasma EBV DNA at diagnosis had EBV‐negative lymphomas, as confirmed by multiple methods. Even in these HIV‐positive patients with EBV‐negative DLBCL, high plasma EBV DNA remained associated with shorter OS (P =.014). These results suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive patients with convincingly EBV‐negative DLBCL, extending the potential utility of EBV measurement as a valuable and implementable prognostic marker in SSA. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. Modified EPOCH for high‐risk non‐Hodgkin lymphoma in sub‐Saharan Africa.

Author

Zuze, Takondwa, Ellis, Grace K., Kasonkanji, Edwards, Kaimila, Bongani, Nyasosela, Richard, Nyirenda, Ruth, Tomoka, Tamiwe, Mulenga, Maurice, Chikasema, Maria, Tewete, Blessings, Mtangwanika, Asekanadziwa, Chiyoyola, Sarah, Chimzimu, Fred, Kampani, Coxcilly, Mhango, Wilberforce, Nicholas, Simon, Randall, Cara, Montgomery, Nathan D., Fedoriw, George, and Westmoreland, Katherine D.

Subjects
*LYMPHOMAS, *CD4 lymphocyte count, *CONFIDENCE intervals, *TREATMENT effectiveness
Abstract

Aggressive non‐Hodgkin lymphoma (NHL) is among the most common cancers in sub‐Saharan Africa (SSA), where CHOP is standard treatment and outcomes are poor. To address this, we treated 17 newly diagnosed adult patients in Malawi with Burkitt (n = 8), plasmablastic (n = 8), and primary effusion lymphoma (n = 1) with a modified EPOCH regimen between 2016 and 2019. Twelve patients (71%) were male and the median age was 40 years (range 16‐63). Eleven (65%) were HIV infected, median CD4 count was 218 cells/µL (range 9‐460), and nine (82%) had suppressed HIV RNA < 400 copies/mL. Patients received a median of six cycles (range 2‐8) and median follow‐up was 14 months (range 2‐34) among patients still alive. Grade 3/4 neutropenia was observed in 26% of cycles and in 65% of patients. Sixteen (94%) responded to EPOCH and 10 (59%) achieved a complete response. One‐year overall survival (OS) was 62% (95% confidence interval [CI], 42%‐91%). Five patients (29%) died from progressive NHL and three (18%) from treatment‐related complications. These data suggest EPOCH with setting‐appropriate modifications may be a practical, safe, and effective option for improving high‐risk NHL outcomes in Malawi and comparable settings, which deserves further prospective evaluation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Mature outcomes and prognostic indices in diffuse large B‐cell lymphoma in Malawi: a prospective cohort

Author

Painschab, Matthew S., primary, Kasonkanji, Edwards, additional, Zuze, Takondwa, additional, Kaimila, Bongani, additional, Tomoka, Tamiwe, additional, Nyasosela, Richard, additional, Nyirenda, Ruth, additional, Dhungel, Bal M., additional, Mulenga, Maurice, additional, Chikasema, Maria, additional, Tewete, Blessings, additional, Mtangwanika, Asekanadziwa, additional, Chiyoyola, Sarah, additional, Mhango, Wilberforce, additional, Chimzimu, Fred, additional, Kampani, Coxcilly, additional, Krysiak, Robert, additional, Shea, Thomas C., additional, Montgomery, Nathan D., additional, Fedoriw, Yuri, additional, and Gopal, Satish, additional

Published
2018
Full Text
View/download PDF

22. A prospective description of HIV-associated multicentric Castleman disease in Malawi

Author

Tomoka, Tamiwe, primary, Painschab, Matthew S., additional, Montgomery, Nathan D., additional, Seguin, Ryan, additional, Mulenga, Maurice, additional, Kaimila, Bongani, additional, Kasonkanji, Edwards, additional, Zuze, Takondwa, additional, Nyasosela, Richard, additional, Nyirenda, Ruth, additional, Chikasema, Maria, additional, Tewete, Blessings, additional, Mtangwanika, Asekanadziwa, additional, Chiyoyola, Sarah, additional, Chimzimu, Fred, additional, Kampani, Coxcilly, additional, Fedoriw, Yuri, additional, and Gopal, Satish, additional

Published
2018
Full Text
View/download PDF

23. Understanding Breast Cancer and Improving Outcomes in Malawi

Author

Zuze, Takondwa, primary, Tomoka, Tamiwe, additional, Nyirenda, Ruth, additional, Nyasosela, Richard, additional, Seguin, Ryan, additional, Chilima, Chrissie, additional, Kudowa, Everista, additional, Kumwenda, Wiza, additional, Chikasema, Maria, additional, Tewete, Blessings, additional, Mtangwanika, Asekanadziwa, additional, Chiyoyola, Sara, additional, and Gopal, Satish, additional

Published
2018
Full Text
View/download PDF

24. DLBCL outcomes in Malawi: Effect of HIV and derivation of a simplified prognostic score.

Author

Painschab, Matthew, primary, Kasonkanji, Edwards, additional, Zuze, Takondwa, additional, Kaimila, Bongani, additional, Tomoka, Tamiwe, additional, Dhungel, Bal, additional, Mulenga, Maurice, additional, Chikasema, Maria, additional, Tewete, Blessings, additional, Mtangwanika, Asekanadziwa, additional, Chiyoyola, Sarah, additional, Mhango, Wilberforce, additional, Chimzimu, Fred, additional, Kampani, Coxcilly, additional, Krysiak, Robert, additional, Shea, Thomas C., additional, Montgomery, Nathan, additional, Fedoriw, Yuri, additional, and Gopal, Satish, additional

Published
2018
Full Text
View/download PDF

25. Mature outcomes and prognostic indices in diffuse large B‐cell lymphoma in Malawi: a prospective cohort.

Author

Painschab, Matthew S., Kasonkanji, Edwards, Zuze, Takondwa, Kaimila, Bongani, Tomoka, Tamiwe, Nyasosela, Richard, Nyirenda, Ruth, Dhungel, Bal M., Mulenga, Maurice, Chikasema, Maria, Tewete, Blessings, Mtangwanika, Asekanadziwa, Chiyoyola, Sarah, Mhango, Wilberforce, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Shea, Thomas C., Montgomery, Nathan D., and Fedoriw, Yuri

Abstract

Summary: Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109/l (interquartile range [IQR] 0·062–0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow‐up and the 2‐year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age‐adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource‐limited settings but requires validation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. Plasmablastic lymphoma in Malawi

Author

Mulenga, Maurice, Zuze, Takondwa, Dhungel, Bal M, Painschab, Matthew S, Fedoriw, Yuri, Chikasema, Maria, Seguin, Ryan, Ntangwanika, Asekanadziwa, Montgomery, Nathan D, Tewete, Blessings, Kudowa, Evarista, Chimzimu, Fred, Chiyoyola, Sarah, Gopal, Satish, Tomoka, Tamiwe, Kampani, Coxcilly, Krysiak, Robert, Kasonkanji, Edwards, and Kaimila, Bongani

Subjects
3. Good health
Abstract

Plasmablastic lymphoma (PBL) clinical descriptions are scarce from sub-Saharan Africa (SSA) where both HIV and EBV are highly endemic. We identified 12 patients with pathologically confirmed PBL from a prospective cohort in Lilongwe, Malawi. Median age was 46 (range 26–71), seven (58%) were male, and six (50%) were HIV-positive. Eight patients were treated with CHOP and four with a modified EPOCH regimen. One-year overall survival was 56% (95% CI 24–79%), without clear differences based on HIV status. PBL occurs in Malawi in HIV-positive and HIV-negative individuals and can be treated successfully with curative intent, even in a low-resource setting in SSA.

27. A prospective description of HIV-associated multicentric Castleman disease in Malawi.

Author

Tomoka T, Painschab MS, Montgomery ND, Seguin R, Mulenga M, Kaimila B, Kasonkanji E, Zuze T, Nyasosela R, Nyirenda R, Chikasema M, Tewete B, Mtangwanika A, Chiyoyola S, Chimzimu F, Kampani C, Fedoriw Y, and Gopal S

Subjects
Adult, Anti-Retroviral Agents, Case-Control Studies, Castleman Disease drug therapy, Castleman Disease epidemiology, Castleman Disease virology, Drug Therapy, Combination, Female, Follow-Up Studies, HIV drug effects, HIV Infections drug therapy, HIV Infections virology, Humans, Malawi epidemiology, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Castleman Disease mortality, HIV isolation & purification, HIV Infections complications
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results